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Abstract
Background: Growing imperatives for safety, quality and responsible resource allocation have prompted renewed
efforts to identify and quantify harmful or wasteful (low-value) medical practices such as test ordering, procedures
and prescribing. Quantifying these practices at a population level using routinely collected health data allows us to
understand the scale of low-value medical practices, measure practice change following specific interventions and
prioritise policy decisions. To date, almost all research examining health care through the low-value lens has
focused on medical services (tests and procedures) rather than on prescribing. The protocol described herein
outlines a program of research funded by Australia’s National Health and Medical Research Council to select and
quantify low-value prescribing practices within Australian routinely collected health data.
Methods: We start by describing our process for identifying and cataloguing international low-value prescribing
practices. We then outline our approach to translate these prescribing practices into indicators that can be applied
to Australian routinely collected health data. Next, we detail methods of using Australian health data to quantify
these prescribing practices (e.g. prevalence of low-value prescribing and related costs) and their downstream health
consequences. We have approval from the necessary Australian state and commonwealth human research ethics
and data access committees to undertake this work.
Discussion: The lack of systematic and transparent approaches to quantification of low-value practices in routinely
collected data has been noted in recent reviews. Here, we present a methodology applied in the Australian context
with the aim of demonstrating principles that can be applied across jurisdictions in order to harmonise
international efforts to measure low-value prescribing. The outcomes of this research will be submitted to
international peer-reviewed journals. Results will also be presented at national and international
pharmacoepidemiology and health policy forums such that other jurisdictions have guidance to adapt this
methodology.
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Background
There is a growing recognition in health care that less
may actually be more and that safety and effectiveness
may be compromised in the face of ‘too much medicine’
[1]. A recent US study examining regional variation in
test ordering, procedures and prescribing found that up
to 30% of practices are potentially harmful or wasteful
[2]. Moreover, health care costs are spiralling due to the
increasing volume of services and interventions for age-
ing populations and the introduction of new and emer-
ging high-cost services and treatments. Low-value
practices, including tests, procedures and prescribing
that provide little or no benefit, may result in patient
harm or wasted resources [3]. The process of identifying
harmful or wasteful practices is not new, but the field
has gathered renewed global momentum and publicity
because of growing imperatives to maximise safety, ef-
fectiveness and benefits from health care investments
[4]. There is a need to quantify nominated low-value
practices at the population level in order to benchmark
current activities, prioritise policy initiatives and measure
changes resulting from policy interventions [5].
Low-value prescribing practice nomination
There have been numerous attempts to systematically
nominate low-value or inappropriate prescribing practices.
However, in many circumstances, a lack of provider and
public consultation has led to feelings of top-down steward-
ship and rationing [6–8]. Physician-led, consensus-based
guidelines such as the Beers and STOPP criteria [9, 10]
have also been developed to identify potentially inappropri-
ate prescribing practices, but these tend to focus on specific
populations (such as the elderly). Recent campaigns con-
ducted through the lens of ‘low-value care’ have coalesced
into the creation of specialty-specific, national lists of low-
value practices that are not necessarily restricted to specific
sub-populations [3]. Since 2007, the UK’s National Institute
of Health and Care Excellence (NICE) has curated the ‘do
not do’ guidance in association with the Cochrane Collabor-
ation [6]. Similarly, the Choosing Wisely campaign is a
grassroots physician-led program that was launched for-
mally in 2012 in the USA and has since spread to Canada,
Australia, Japan and Europe [11]. This program aspires to
be a transparent and consistent process of speciality-wide
consultation, in collaboration with patient representatives
to nominate specialty-based ‘top 5 lists’ of low-value prac-
tices based on evidence [12] and shared values [7]. There
are a number of other similar current initiatives detailing
low-value practices within medicine such as the Royal
Australasian College of Physicians’ EVOLVE program, the
British Medical Journal’s Too Much Medicine series and
the Journal of the American Medical Association’s Less is
More series [13–15].
Low-value prescribing practice quantification
The science of measuring low-value care is in its infancy.
At the population level, quantification aims to determine
the frequency of low-value practices as well as variation
(geographical or by other factors), changes over time,
associations with patient and provider characteristics
and downstream health consequences and costs [5].
Recent advances in analytical methods and access to
routinely collected health data have created possibilities
for quantifying low-value care at the population level
[16–18]. However, a major challenge is that many nomi-
nated practices and downstream consequences are finely
nuanced and identify specific populations and clinical
contexts that may not be recorded within routinely
collected data [8].
There have been efforts to quantify harmful or waste-
ful prescribing using routinely collected data prior to the
low-value movement [19], but attempts to systematically
review the historical literature are challenging because of
the lack of common key words and MeSH terms.
Systematic reviews of pharmacoepidemiological studies
undertaken using Australian and Nordic routine data
collections found that studies quantifying harmful and/
or wasteful practices were in the minority [20, 21]. Some
examples include measuring the extent of potentially
inappropriate medication use in the elderly [22, 23] and
consensus-based lists of inappropriate psychotropic pre-
scribing [24]. Following the evolution of low-value lists,
there have been some efforts to benchmark low-value
practice frequency and quantify the impact of the
Choosing Wisely campaign using routine data collec-
tions. A recent systematic review of low-value measures
identified a lack of transparency in translating practices
into indicators and the need to validate any measures
that are developed [25]. Studies to date have also tended
to focus on low-value tests and procedures rather than
on prescribing [26–28]. These studies use varying quan-
tification approaches, thus limiting direct comparisons,
and so, there is a need to standardise this methodology
to enhance the global effort.
Therefore, the objectives of this research program are
to detail methods for:
 Cataloguing nominated low-value prescribing practices
from low-value lists published internationally. This
process is ongoing and will be updated to incorporate
additional practices appearing on international lists.
 Translating low-value prescribing practices into
indicators that can be applied to Australian routine
data collections.
 Quantifying the extent of low-value prescribing
practices in Australia.
 Quantifying the downstream consequences of
low-value prescribing practices in Australia.
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The principles outlined in this protocol paper are gen-
eralisable to research in other jurisdictions attempting to
quantify low-value prescribing practices in their routine
data collections.
Methods
Cataloguing low-value prescribing practices
We are creating a catalogue of low-value prescribing
practices by extracting nominated practices from inter-
national Choosing Wisely lists. Table 1 summarises the
number of prescribing practices within each list as of
August 2016 (full list of all practices available on request
from authors). Collectively, these Choosing Wisely lists
contain 189 individual prescribing practices representing
22% of all medical practices within these lists. We will
update our catalogue as these lists continue to grow and
other countries become engaged with the Choosing
Wisely campaign.
Duplication of practices within and between lists
After identifying specific practices from the lists, we will
break them into component parts: medication(s), indica-
tion(s), population(s) of intended use and other specifi-
cations. This assists with subsequent translation to
indicators as part of the measurement process (described
below). After grouping practices according to these
components, we will identify similarities both within
(when the practice was nominated by two different spe-
cialty groups on the same jurisdictional list) and between
jurisdictional lists. In some cases, the practices will be
an exact duplication. For example, within the Choosing
Wisely USA list, ‘Don’t use antipsychotics as first choice
to treat behavioural and psychological symptoms of
dementia’ is specified using identical wording within both
the American Society for Geriatrics and the American
Psychiatric Association top 5 lists. In other instances, lists
will nominate the same practice but use different wording.
We also anticipate that similar practices may only have
some common components, often meaning that they are
broader or narrower definitions of a low-value practice.
Defining broader and narrower definitions of low-value
practices
Schwartz et al. [18] recognised that definitions of indi-
vidual low-value practices vary within and across lists,
meaning that broader and narrower definitions of similar
practices may be measured to determine a range over
which similar practices occur. The narrowest definition
likely captures the most certain instances of low-value
care but may exclude some cases classified as low value
by other similar practices. In contrast, the broadest likely
captures all instances but may also include some in-
stances of care defined as appropriate by other similar
practices. Where possible, we will identify broader and
narrower definitions within lists of similar prescribing
practices by identifying increasingly narrower definitions
within the medicine component of the practice: medi-
cine class, subclass or individual medicine. Within the
indication component, we will specify organ-level disor-
ders (broader) versus specific diagnoses (narrower). We
will also identify prescribing practices with the same
medicine and indication that specify subpopulations (e.g.
by specifying an age range) and others that add caveats
(within the ‘other specifications’ component) such as
‘first-line treatment’. For groups of practices with shared
components, we will order the components of each pre-
scribing practice according to whether they are broader
or narrower than the corresponding components of
other practices within the group (illustrated in Fig. 1).
Translating low-value prescribing practices into indicators
applied to Australian routine data collections
In this section, we first detail the study setting and the core
characteristics of Australia’s routinely collected data as they
pertain to the development of prescribing indicators and
quantification of low-value prescribing practices. Second, we
will detail the methods we will use to translate low-value
practices into indicators applied to these data collections.
Australia’s health care setting
Australia has a publicly funded universal health care
system entitling all Australian citizens and permanent
residents to a range of subsidised health services. This
includes free treatment in public hospitals (funded
jointly by the commonwealth and state/territory govern-
ments) and subsidised treatment in private hospitals
(funded jointly by the commonwealth and private health
Table 1 Number of prescribing practices by Choosing Wisely




























aPrescribing practices may be represented more than once within and
between lists
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insurance). It also includes a range of subsidised out-
patient services including consultations with medical
and selected health care professionals (funded by the
commonwealth’s Medicare Benefits Scheme (MBS)) and
medicines prescribed in the community and private
hospitals and on discharge from some public hospitals
(funded by the commonwealth’s Pharmaceutical Benefits
Scheme (PBS); medicines prescribed to public hospital
inpatients are covered primarily by hospital budgets). In
addition, the Australian Government Department of
Veterans’ Affairs (DVA) funds the health care of eligible
veterans, war widows and widowers and their depen-
dants. DVA clients are eligible to receive all health
services and pharmaceuticals accessible to the general
Australian population and, depending on their level of
entitlement, additional DVA-approved services and
pharmaceutical items. Historically, DVA data have been
the primary data source for pharmacoepidemiological
research in Australia as they are a sole payer and main-
tains custodianship over a wide variety of routine data
collections including dispensing and medical service
claims and hospitalisations.
Australia’s routine data collections
We restrict our commentary in this section to data
collections (either stand-alone or linked to each other)
that have the capacity to track individual patients over
time. These collections are summarised in Table 2.
There are two main sources of medicine data: (1)
population-based pharmaceutical claims (payment) data
captured after a prescribed medicine has been dispensed
and subsidised under the PBS and (2) prescribing data
captured at the point of care.
Pharmaceutical Benefits Scheme data
PBS claims will be the primary data source for the
research program outlined in this protocol. Using
dispensing claims data, we have the capacity to estimate
temporal trends in dispensing as well as patterns of
exposure (e.g. initiation, duration of use, dose and dis-
continuation) at the person level. PBS dispensing claims
data also contain demographic details about the patient,
such as age, gender and geographic location of resi-
dence, and also have the capacity to track prescriber
behaviour through a unique prescriber identification
number, although there is limited additional information
about prescriber characteristics beyond their specialty of
practice. PBS claims do not contain information such as
the prescribed daily dose of a medicine or the indication
for which a medication is prescribed. These features of
PBS claims data are typical of dispensing claims data
worldwide [29].
Fig. 1 Example of categorising prescribing practices into broader and narrower definitions
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Prescribing data
Currently, Australia does not have any population-based,
routinely collected prescribing datasets. Rather, data can be
obtained and complied from individual community med-
ical practices or public hospitals. Most general practices in
Australia use electronic prescribing platforms that have the
capacity to capture prescribing of PBS-listed and other
medicines, but this is not necessarily the case in specialty
practice [30, 31]. Medicines prescribed to public hospital
inpatients are funded primarily by hospital budgets at the
state level, and electronic prescribing systems have become
increasingly commonplace in Australian public hospitals.
Significant challenges currently exist in Australia in terms
of unifying prescribing data across more than one hospital
network and multiple community practices, due in part to
the high degree of variability in software used and local
governance arrangements. In addition, the quality and
comprehensiveness of prescribing data is highly variable
and dependent on end-user inputs.
However, one of the most promising prescribing datasets
that has the potential for use in our study is from the
MedicineInsight initiative [32], an Australian Government-
funded programme that aims to increase the understanding
of prescribing behaviour in Australian general practice.
Comprising approximately 500 practices throughout
Australia, it is the first large-scale, longitudinal general
practice data program in Australia that extracts de-
identified patient health records from existing general prac-
tice software. Compared with PBS dispensing data, these
data contain greater depth of clinical information about the
practice, the prescriber and the patient, as well as the clin-
ical indication(s) for which the medicine is prescribed, tests
are ordered and referrals are made [33]. However, because
this is a relatively new program and general practice re-
cruitment is ongoing, it is unclear how nationally-
representative the data are currently.
Prescribed medicine data linked to other routinely collected
datasets
We will utilise a range of population-based data com-
prising PBS dispensing claims linked to other routine
collections held by the Commonwealth of Australia
(Medicare service claims) and the individual states
(hospitalisations, emergency department visits, cancer
notification, fact and cause of death data) to implement
our proposed research. For the purposes of the specific
Table 2 Australian datasets (stand-alone or linked) available to quantify low-value prescribing practices
Dataset Variables of interest
Medicines prescribed in the community
Dispensing
Dataset: Pharmaceutical Benefits Scheme (PBS) dispensing
claims. Available 2005 to current
Custodian: Australian Government Department of Human Services
Item number, date of prescribing and dispensing service, patient co-payment,
cost to government, patient demographics (age, gender, location of residence
mapped to Socioeconomic Index and Remoteness classifications), provider
location (also mapped), fact of death
Prescribing
Dataset: MedicineInsight. Available 2010 to current
Custodian: NPS MedicineWise
Prescribed medicines (date of prescribing; prescribed daily dose; indication for
prescribing), test ordering (date of request, results), patient demographics (age,
gender, location of residence mapped to Socioeconomic Index and Remoteness
classifications), patient past medical and family history, referrals, management
plans, immunisations, provider location (also mapped)
Datasets to which PBS dispensing data will be linked
Tests, procedures and outpatient consultations
Dataset: Medical Benefits Schedule (MBS) service claims.
Available 2004 to 2013
Custodian: Australian Government Department of Veterans Affairs
Item number, date of service, scheduled fee, provider charge, benefits paid,
patient co-payment, patient demographics (age, gender, location of residence
mapped to Socioeconomic Index and Remoteness classifications), provider
location (also mapped)
Hospitalisations
Dataset: NSW Admitted Patient Data Collection
Available July 2000 to current
Custodian: Director, Demand and Performance Evaluation Branch,
NSW Department of Health
Diagnostic and procedure codes, diagnosis-related groups (admission costs),
hospital type, separation date and status, geographic location of patient
residence and hospital; patient demographics (age, gender, place of residence)
Emergency department visits
Dataset: NSW Emergency Department Data Collection. Available
2005 to current
Custodian: Director, Demand and Performance Evaluation Branch,
NSW Department of Health
Triage category, diagnostic codes; mode of arrival; hospital type, geographic
location of patient residence and hospital, separation date and status, patient
demographics (age, gender, place of residence)
Cancer notifications
Dataset: NSW Central Cancer Registry. Available 1994 to current
Custodian: Central Cancer Registry NSW
Date of new cancer diagnosis, type of cancer, stage at diagnosis
Death data
Dataset: Registry of Births, Deaths and Marriages NSW. Available
1994 to current
Custodian: Registrar of Births, Deaths and Marriages NSW
Cause of death, place of death, date of death, decedent demographics
(age, gender, place of usual residence)
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quantification, the example outlined below will use the
DVA linked dataset, a data source that has been used ex-
tensively in Australian pharmacoepidemiological studies
[20]. However, for future work quantifying other pre-
scribing practices, we may use other linked datasets.
Table 2 outlines the population-based collections that
have been linked to dispensing claims data within the
DVA dataset. The advantage of such linked collections is
that they provide a more detailed picture of an individ-
ual’s health that can be helpful when attempting to iso-
late low-value practices. Linked data also enhance the
capacity to establish the downstream consequences of
low-value care and to account for confounders when per-
forming outcome studies. While it is technically feasible
to link prescribed medicine data at the individual level to
other routine data collections, currently it will only yield
data for a (non-representative or biased) sample of hos-
pital or community settings in Australia. Efforts to link
pathology results data to pharmaceutical dispensing
claims on a national level are limited in Australia due to
the multitude of pathology services, and as with integrat-
ing hospital prescribing nationally, there is a high degree
of variability in software used and local governance
arrangements.
Indicator development and application
We will construct indicators by matching the compo-
nent parts of prescribing practices to variables within
routinely collected data. The collection of variables cor-
responding to a prescribing practice will represent the
practice indicator. For the purposes of illustration, we
have selected nine practices identified from the Choos-
ing Wisely lists (Table 3). These practices represent the
broadest definitions within their groups of similar prac-
tices. Practices that are similar but narrower are listed in
Additional file 1: Table S1. In the simplest case, the
components of the practice ‘don’t prescribe benzodiaze-
pines to elderly people’ are benzodiazepines (medicine)
and elderly people (population). Medicine and age are
both variables within pharmaceutical dispensing claims
data, and so, the indicator would consist of exposure to
benzodiazepines and a defined age group and this prac-
tice could be measured in stand-alone PBS data.
When we are unable to directly translate prescribing
practices into indicators, as they contain components
that do not have equivalent variables within existing
datasets, we will create proxy measures from existing
variables. For instance, the practice ‘avoid antipsy-
chotics in dementia’ is comprised of antipsychotics
(medicines) and dementia (indication). If attempting to
quantify this within dispensing claims data alone, where
indication for prescribing and information on co-
morbidities are generally not available, we will create
proxy markers for disease states (such as the prior
dispensing of an anti-dementia medication). Similarly,
for the practice ‘Don’t routinely prescribe two or more
antipsychotic medications concurrently’, we will use a
proxy for medication concomitance within dispensing
claims data as the intended duration of exposure
following a medication dispensing is not known. The
uncertainty introduced by these proxies can be some-
what mitigated if dispensing claims are linked to other
data sources such as hospitalisation data, which contain
hospitalisation-related diagnostic codes. While the de-
gree of uncertainty introduced by these proxy measures
is difficult to quantify, we will perform sensitivity ana-
lyses, such as varying the boundaries of decision rules
within these proxy variables to observe the magnitude
of the effect on practice quantification. Prescribing data
can also be used if an indication is required and cannot
be inferred from dispensing claims or hospitalisations.
However, as previously discussed, the quality of diag-
nostic information is end-user dependent and we aim
to focus on dispensing claims for this Australian ana-
lysis as the generalisability of findings from existing
Australian prescribing data are unclear. Furthermore,
we do not currently have access to dispensing claims
linked to pathology data. However, in the interests of
this protocol being adaptable to an international audi-
ence, we have included prescribing and pathology data
at the stage of indicator translation. Table 4 illustrates
Table 3 Low-value prescribing practice case examples and





1 Avoid prescribing antibiotics
for upper respiratory infections
USA
2 Don’t use benzodiazepines in
the elderly
International
3 Avoid long-term PPI therapy
for GI symptoms
International
4 Avoid antipsychotics for dementia International
5 Do not use antibiotics in
asymptomatic bacteriuria
Australia
6 Don’t recommend the regular




7 Don’t prescribe testosterone
therapy unless there is evidence
of proven testosterone deficiency
Australia
8 Don’t initiate and continue
medicines for primary prevention
in individuals who have a limited
life expectancy
Australia
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how the nine exemplar prescribing practices (Table 3)
can be translated into their corresponding indicators in
Australian data.
There may often be several approaches to quantifying
the same practice that vary in accuracy and precision by
using different indicators comprised of a range of differ-
ent variables, potentially from different data sources.
When adapting these methods to other jurisdictions, the
most appropriate approach depends on local data access,
coverage and analytical expertise.
Quantifying the extent of a low-value prescribing practice
in Australia
Our research program will undertake a series of observa-
tional cohort studies to quantify the extent of low-value
prescribing in Australia. In this section, we describe
specific quantification methodology for one low-value
prescribing practice, ‘Don’t routinely prescribe two or
more antipsychotic medications concurrently’, specified
within the USA Choosing Wisely list and hereafter
referred to as antipsychotic polypharmacy. The general
approach outlined here will apply to all of the low-value
prescribing practices detailed in this protocol when we
utilise PBS claims linked with other routine collections.
Cohort definition
We will use stand-alone Pharmaceutical Benefits Scheme
(PBS) dispensing claims from 1 March 2005 to the most
contemporary available (currently January 2017) to per-
form our analysis [34] (Table 2). We will identify people
dispensed antipsychotics (WHO Anatomical Therapeutic
Classification codes NO5A) and define antipsychotic
concomitance as overlapping courses of two or more
non-like antipsychotics for 60 days or more. However,
we will also perform sensitivity analyses using 14- and
90-day cutoffs. PBS dispensing claims contain only the
date medicines are dispensed, and so, to identify courses
of antipsychotics, we will first estimate the duration of
exposure (in days) following a single dispensing of each
antipsychotic medicine, hereafter referred to as the esti-
mated period of exposure (EPE). For each antipsychotic,
we will measure the intervals between dispensings of the
same medicine in individuals who have more than one
dispensing of that medicine over the study period. The
EPE for a medicine will then be calculated as the num-
ber of days in which 75% of people have received a sub-
sequent dispensing of the same medicine. A course of a
given antipsychotic medicine will be defined as the
period in which there are serial dispensings of the same
medicine and the EPEs of these dispensings overlap.
This method has been applied previously to psychotro-
pics and accounts for variability in dispensing due to ad-
herence, dose changes and seasonality [35, 36].
Practice quantification
We will quantify the extent of and variability in anti-
psychotic polypharmacy. Specifically, we will determine:
(a)The number of patients experiencing antipsychotic
polypharmacy expressed as a proportion of all
people treated with antipsychotics. We will calculate
the number of episodes of antipsychotic
polypharmacy as well as the number (mean, median,
interquartile range (IQR) and maximum and
minimum) of episodes per patient. We will describe
this cohort according to age, gender, location of
residence, rurality and socioeconomic stratum.
(b)The number of prescribers delivering low-value
prescribing expressed as a proportion of the total
number of prescribers in the study cohort. We
will also calculate the number (means, medians,
interquartile ranges and maxima and minima) of
episodes of antipsychotic polypharmacy
per prescriber and whether antipsychotic
polypharmacy was initiated or continued by
that prescriber. We will then describe these
prescribers according to available prescriber
variables. Within the PBS dispensing claims,
this is limited to speciality, but in other datasets,
in particular prescribing data, additional variables
include number of years in practice and rurality
and
socioeconomic characteristics of practice location.
(c)Variation in low-value care. We will examine the
variation in antipsychotic polypharmacy by stratifying
analyses according to prescriber location (rurality
and socioeconomic stratum of practice location)
and patient characteristics (age, gender, location
of residence, rurality and socioeconomic stratum)
using established methodology [37, 38]. We will
also use Poisson, negative binomial and/or multilevel
regression models to determine the influence of these
patient and provider characteristics on antipsychotic
polypharmacy counts [39].
(d)Changes over time and following policy
intervention. Analyses a. to c. will be annualised to
demonstrate changes over time. We will calculate
the prevalence and incidence of antipsychotic
polypharmacy where prevalent use is defined as
persons with at least one episode of antipsychotic
polypharmacy within a given calendar year and
incident (new) use is defined as persons with an
episode of antipsychotic polypharmacy within a
given calendar year and no episode of antipsychotic
polypharmacy in the previous 12 months.
Additionally, we will use interrupted time series
analyses as previously applied to PBS dispensing
claims [40, 41] to examine changes in antipsychotic
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polypharmacy before and after interventions that
may impact on this practice. An example of such
an intervention in Australia that will be investigated
is the change in the prescribing restrictions for
antipsychotics that had required telephone authority
but moved to streamlined authority on 1 July 2007
[42]. With fewer barriers to prescribing, this may
have increased antipsychotic polypharmacy. Given
concerns about antipsychotic polypharmacy, this
may prompt a review of prescribing authority policy.
We will use an autoregressive integrated moving
average (ARIMA) approach using the Box-Jenkins
method which will be used to model subsequent
time series while accounting for seasonal variability,
as well as long-term trends and autocorrelation [43].
Quantification of downstream consequences
Here, we start with a discussion regarding the general
concepts involved in quantifying downstream conse-
quences of low-value prescribing practices within rou-
tinely collected data and then return to detail how these
are applied to quantify the downstream consequences of
antipsychotic polypharmacy. Low-value prescribing prac-
tices may expose individuals to additional, unnecessary
risks, and investigating the measurable harms of these
practices is an important research endevour. Adverse
drug events (ADEs) known to be associated with each
practice will be identified from the literature, and valid
indicators corresponding to these ADEs subsequent to
an index dispensing will be identified within routinely
collected health datasets. These may be medicine-based
ADE indicators such as the dispensing of a medicine
known to be associated with an ADE or diagnostic indi-
cators, such as ICD-10 codes in hospitalisation data or
the International Classification of Primary Care (second
edition) classification (ICPC) system used in general
practice. ADE [44] and disease state [45] indicators have
been validated in Australian veterans’ affairs data. While
disease state indicators were validated to measure co-
morbidity, they also have clinical face validity as ADE
markers. Generally, these ADE indicators have been
shown to have good specificity but lower sensitivity
when compared to the gold standards of record review
and self-reported health surveys [44–46]. The other limi-
tation is that they vary in how accurately they reflect the
actual timing of onset of the ADE. Additional file 2:
Table S2 identifies the potential ADEs associated with
each prescribing practice example in Table 3, and Add-
itional file 3: Table S3 details the potential medicine and
diagnostic-based indicators of these adverse drug events.
Antipsychotic polypharmacy has been associated with
increased risk of parkinsonism, dyslipidaemia, cardio and
cerebrovascular disease, diabetes, cognitive impairment
and sudden cardiac death (Additional file 2: Table S2)
[47].Using the same study cohort and study period defined
above, we will use prescription sequence analysis [44] to
determine the association of antipsychotic polypharmacy
with an incident dispensing (i.e. new dispensing with no
dispensings in the 12 months prior) of these ADE
medicine-based indicators. The crude sequence ratio will
be calculated by dividing the number of people with an
incident dispensing of an ADE indicator medicine in a 12-
month post-exposure period (after the start of anti-
psychotic polypharmacy) with the number of people with
incident dispensing of an ADE indicator medicine in a
12-month pre-exposure period (before the start of anti-
psychotic polypharmacy). We will perform sensitivity
analyses, varying the length of pre- and post-exposure
periods (3, 6 and 18 months). We will estimate the
probability that the ADE medicine is dispensed first, in
the absence of any causal relationship, adjusting for the
null-effect sequence ratio which accounts for under-
lying changes in the incidence of dispensing of the ADE
medicine (see [48] for details and formula). We will
then calculate the adjusted sequence ratio (ASR) by
dividing the crude by the null-effect ratio, and 95%
confidence intervals will be calculated for this value. A
signal is considered to be present when the lower limit
of the 95% CI is one or more.
When dispensing claims data are linked to other health
databases, a greater range of outcome variables are avail-
able. In these cases, cohort and case-control study designs
with appropriate regression analyses [49] can be used to
quantify the association between an index prescribing
event and an ADE using an appropriate ADE indicator
while adjusting for patient and prescriber factors. Choice
of study design will depend on the known natural history
of the ADE, its temporal relationship to the low-value
practice exposure and the availability of a control group.
In this specific example, we will apply a self-controlled
case series analysis to determine whether antipsychotic
polypharmacy leads to increased risk of acute vascular
disease. This will require linkage of PBS dispensing
claims and hospitalisation data, and for this purpose, we
have access to Department of Veterans Affairs (DVA)
linked dataset (Table 2). Self-controlled case series
analysis effectively measures incidence rate ratios of rela-
tively acute ADEs while controlling for measured and
unmeasured fixed patient confounders [50, 51]. We will
use PBS dispensing claims linked to hospitalisation data for
DVA beneficiaries from 1 January 2006 and 31 December
2015 but results will be reported from 1 January 2007 to
allow for a 1-year look-back when identifying incident
antipsychotic polypharmacy. Patients will be eligible for
inclusion if they have hospital diagnostic codes related to
acute ischemic heart disease (ICD-10: I20-24) and
stroke (ICD-10: I60-I64) during the study period and
if they had been full entitlement holders (eligible for
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all health services) for at least 12 months at the time
of diagnosis. Incident antipsychotic polypharmacy (i.e.
new episodes with no episodes in the 12 months
prior) will be identified for these individuals during this
period. The end of antipsychotic polypharmacy will be de-
fined as one EPE after the last concomitant antipsychotic
dispensing. As previously described [52] exposed person-
time will be divided into 1, 2 to 4 and 5 to 12 weeks after
the start of antipsychotic polypharmacy. A pre-exposure
risk period will also be divided into 1, 2 to 4 and 5 to
12 weeks prior to the start of antipsychotic polypharmacy,
and this will be considered separately from non-exposed
time to account for confounding by indication (i.e. in the
case that polypharmacy was initiated as a consequence of
hospitalisation). Some individuals will have no exposure to
antipsychotic polypharmacy for the entire study period
but will be included in the analysis to contribute informa-
tion about possible confounders. The count of outcomes
in each of these exposure risk periods will be compared
with the count of outcomes in non-exposed periods. Con-
ditional Poisson regression will be used to calculate inci-
dence rate ratios for the two primary outcomes
(hospitalisation with ischemic heart disease or stroke)
adjusting for age, gender and calendar year.
Incremental costs
We will use dispensing claims data to calculate the
medication costs to the payer (government or private
health care fund) and out-of-pocket costs to the patient
for psychotropic polypharmacy and compare these costs
to antipsychotic monotherapy. Excess hospitalisations
with cardiovascular diseases and stroke will be extrapo-
lated from incidence rate ratios, and excess costs will be
calculated using length of stay and hospital diagnosis-
related groups (DRGs) [53].
Ethics
The Population Health Sciences Research Ethics Commit-
tee has granted approval for our overall program of re-
search (Approval Numbers 2013/11/494 and 2014/06/539).
Consent and privacy considerations
A combination of commonwealth, state, hospital and
privately held data will be used as part of this program
of work.
The use and disclosure of commonwealth and state
data are governed under the Privacy Act 1988 and
Health Records and Information Privacy (HRIP) Act
2003, respectively. We were able to access this data with
a waiver of consent as under this legislation, it is not
required if (1) it is impracticable to gain consent and (2)
the use is in accordance with the section 95A guidelines
(which provides a process to resolve the conflict that
may arise between the public interest in privacy and the
public interest in medical research).
We will minimise the risk to personal privacy by
ensuring data are stored securely within the Centre for
Big Data Research located at the University of New
South Wales; only researchers involved in data analysis
will have access to the data and that researchers do not
have access to identified data or any means of re-
identifying individuals within the data. Finally, all data
will be presented in aggregated form only, and poten-
tially identifiable information will not be published. We
will suppress data with small cell sizes.
Dissemination
The outcomes of this research will be submitted to
international peer-reviewed journals; in particular gen-
eral medical, health policy and pharmacoepidemiology
journals. Furthermore, results will be presented at na-
tional and international pharmacoepidemiology, health
policy and Choosing Wisely forums. Direct access to the
data and analytical files to other individuals or author-
ities is not permitted without the express permission of
the approving human research ethics committees and
data custodians.
Limitations
The potential limitations of this programme of research
relate to low-value lists themselves and the application
of these practices for quantification in routine data
collections. The Choosing Wisely campaign has been
criticised for the inclusion of low-impact, low-value
practices, putatively because of conflict of interest with
revenue streams for specific specialist groups [8]. How-
ever, this appears to be the exception rather than the
rule [8], and one may argue that this is not likely to be
the case for prescribing that typically does not generate
income streams for physicians. The process of practice
translation into indicators highlights limitations of using
routine data collections to quantify prescribing practices
such as inferences and things that cannot be easily mea-
sured. This is one consequence of lists that have been
generated without measurement necessarily in mind and
often results from lack of clinical information within
routine data collections. This can also lead to substantial
unmeasured confounding when attempting to identify as-
sociations between low-value prescribing practices and
downstream ADEs. Using self-controlled study designs
can help mitigate this unmeasured confounding. There is
a need to validate more ADE indicators within Australian
datasets using either medical record review or self-
reported health surveys as gold standards. Issues such as
data coverage and data access also limit generalisability of
results.
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Discussion
The presence of prescribing practices in international
Choosing Wisely initiatives clearly indicates there is
cause for concern regarding low-value prescribing. How-
ever, to date there have been no systematic efforts to
quantify these practices at a jurisdictional level. Further-
more, there have been no efforts to systematically deter-
mine the downstream consequences and associated
costs of these low-value prescribing practices.
We noted similarities in prescribing practices within
and between jurisdictional lists and that similar practices
could be grouped (mostly according to medication and
indication) during our first cataloguing process. Identify-
ing groups of similar practices is one approach to iden-
tify priority areas for practice measurement: large
groups of similar practices may represent shared areas of
concern. They also represent opportunities to harmonise
low-value practice definitions at jurisdictional and inter-
national levels by agreeing on a common list of practices
to endorse. This would greatly assist quantification as
within and between jurisdictional variability in low-value
practice frequency could then be more easily measured
and Choosing Wisely International has already started
this process [54]. Until there is a common international
list, identifying and quantifying broader and narrower
definitions of similar practices allows a range over which
similar practices occur to be identified. This method has
been applied to quantifying tests and procedures [18].
However, compared to low-value tests and procedures,
identifying the narrowest definitions of prescribing prac-
tices can be more challenging due to the greater and
more varied number of components that prescribing
practices are composed of.
As noted previously in our introduction, there are a
number of other low-value lists such as the National
Institute for Health and Care Excellence (NICE) ‘do not
do’ list, the Royal Australasian College of Physicians
EVOLVE project [11] and practices highlighted within
JAMA Internal Medicine's and BMJ's ‘less is more’ and
‘too much medicine’ series, respectively. For the pur-
poses of this protocol, we have focused exclusively on
Choosing Wisely, but we intend on cataloguing all prac-
tices with other lists as they become available. It is import-
ant to note that many of the items identified within the
Choosing Wisely lists are also present in these other lists.
Quantification efforts using routinely collected health
data specifically assist in benchmarking population levels
and costs of low-value practices as well as evaluating the
impact of ensuing policy and practice decisions [5].
These quantification efforts may also directly facilitate
behaviour change by providing methods of non-punitive
audit and feedback to prescribers and patients [22].
Although Australian data has been used as an exem-
plar, it is our intent that these methods can be used by
other jurisdictions as a standard framework to continue
to prioritise and quantify prescribing practices at a juris-
dictional level.
Additional files
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